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Abstract Any evaluation of steroids in kidney transplan-
tation is hampered by individual variability in metabo-
lism, the lack of clinically available steroid blood levels,
and overall little attention to steroid exposure. Many feel
that steroids were an essential part of chronic immuno-
suppression in past decades but may no longer be
necessary in low-risk populations when our newer and
more potent drugs are used. Potential differences in long-
term outcome will be unapparent in short-term antibody
induction studies in low-risk patients, particularly with
l o wo ns t e r o i dd o s e s ,a sm a yh a v eh a p p e n e di nt h e
recent, well-done Astellas trial. In many studies, the
evidence for the superiority of mycophenolate (MMF)
and tacrolimus (TAC) was not as strong as the evidence
for the benefit of steroids in the Canadian cyclosporine
study. As the practice of steroid withdrawal has
increased, we have not seen the improvement in long-
term graft survival that many expected with our newer
agents. Steroids have immunosuppressive effects even in
doses that are low by historic standards, and side effects
may not justify their abandonment.
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Current therapeutic protocols for kidney transplant patients
have markedly reduced the incidence of acute rejection;
however, only modest improvement in long-term outcomes
has been achieved. A major challenge in the application of
current immunosuppressive agents is the narrow therapeutic
window between efficacy and toxicity. In attempts to
minimize toxicity, multiple studies have sought to minimize
or eliminate specific therapeutic agents, most commonly
steroids. Currently, controversy exists on the need to use
glucocorticoids for rejection prophylaxis, and there is no
consensus on the appropriate dosing strategy. This chapter
will review the pertinent pharmacokinetic, pharmacody-
namic, and clinical parameters as they relate to dosing and
the efficacy for glucocorticoids. Many relevant studies and
commentaries have been offered over decades on the effects
of steroid minimization or elimination on clinical outcomes,
including the incidence of chronic rejection, renal function,
and side effects. In this review, references are cited
selectively from this larger body when they illustrate or
summarize an important issue.
Reduction or elimination of immunosuppression without
jeopardizing graft function has long been a goal of the
transplant profession. The point of such dose reduction is
to induce a state of immune “hyporesponsiveness,”
“acceptance,” or “tolerance” to reduce complications of
immunosuppression without increasing the risk of rejec-
tion [1]. Strictly speaking, true immune “tolerance” would
permit permanent withdrawal of immunosuppression. Any
such permissive state would either have to be permanent,
or practical tests would have to be available [2]t o
anticipate loss of such adaptation before irreversible
immunologic or parenchymal change occurred. Immuno-
logically, generation of memory B and T cells which are
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step, although long-term control of efferent responses of
these systems, e.g., by regulatory T cells, could be a
mechanism establishing a hyporesponsive or acceptance
state. A more modest and more common goal of
minimalist steroid regimens is not to reduce overall
immunosuppression but simply to substitute one or more
alternative agents for steroids, without increased risk of
graft loss. Whatever the underlying immunologic theory or
goal, steroids are usually the first agents to be withdrawn
or markedly tapered in an effort to avoid steroid side
effects. However, many recognize that current standard
maintenance steroid doses may have markedly fewer side
effects than previous higher dose regimens [3]. While true
immune accommodation allows minimization of immuno-
suppression, it does not follow that simply tapering
immunosuppression will bring about these states. Rather,
in the general transplant population, tapering immunosup-
pression will usually increase the risk of rejection or graft loss
[4]. The insidious nature of the immune response may mimic
an accommodative state, (“pseudo-accommodation”), but for
unclear reasons, a true hyporesponsive state may unpredict-
ably disappear at a later time [5, 6]. Also, chronic rejection
can develop unpredictably, insidiously, and irreversibly, so
that, “cautious tapering of chronic immunosuppression” is,
in a sense, an oxymoron, given these limitations. Once
rejection ensues and is clinically appreciated, steroid-free
patients are usually placed back on steroids [7], with relative
benefit [8], an event that complicates the interpretation of
many clinical studies.
Glucocorticoids were one of the first classes of medi-
cations used to prevent rejection after solid organ trans-
plantation. Two specific medications, methylprednisolone
and prednisone are used frequently as part of the immuno-
suppressive regimen. Corticosteroids have immunosuppres-
sive, anti-inflammatory and lympholytic effects [9].
Unbound steroid passively diffuses through the cell
membrane into the cell, binds to cytosolic receptors which
causes release of the active receptor, then active receptor
dimers interact with glucocorticoid response elements in
promoter sequences [9]. The net result is decreased
cytokine production, lymphocyte proliferation, and changes
in cellular trafficking. Steroids may preferentially block so-
called proinflammatory TH1 and perhaps Th17 cytokines
[10]. They do not block the release of Il-10 [11], a cytokine
important for T regulatory cell function that has been
suggested to favor hyporesponsiveness to the allograft [12].
Ac o m m o np r o t o c o li nk i d n e yt r a n s p l a n t a t i o ni st o
administer fixed dose intravenous methylprednisolone
perioperatively taper the dosing postoperatively with a
transition to fixed-dose oral prednisone by postoperative
day 3–5. Oral prednisone is typically tapered to physi-
ological doses or a fixed dose of 5 mg for all recipients.
In a study of patients with kidney disease (not trans-
planted), it was documented that the pharmacokinetics of
intravenous methylprednisolone are linear with lower
doses (1–5 mg/kg) and nonlinear when higher doses are
employed (15 mg/kg) [13]. Despite this variability in
exposure, lymphocyte suppression was not affected by
dose, suggesting that dosing above 1 mg/kg exceeds the
critical threshold for suppressing total lymphocyte counts
[13] In studies of kidney transplant recipients, the
pharmacokinetics of intravenous methylprednisolone have
been found to be linear [14]. Additionally, there was a
correlation between exposure and lymphocyte suppression
[14]. This pharmacokinetic-dynamic relationship resulted
in a statistically significant increase in rejection episodes
in patients who had higher clearances of methylpredniso-
lone [14]. This suggests that therapeutic drug monitoring
may be warranted for methylprednisolone in the early
posttransplant period to identify patients with significant
deviations in their pharmacokinetic parameters placing
them at risk for rejection. In the chronic setting, methy-
prednisolone clearance is significantly slower and less
intrapatient variability has been documented [15]. The
mean AUC normalized to a 1-mg dose of methylprednis-
olone was found to be 36.6 ng*h/mL in the acute setting
and 62.1 ng/h/mL in the chronic setting [15].
A marker or panel of markers to predict and monitor
immunologic risk is essential to responsible drug tapering
[2]; however, any conclusions must be somewhat specula-
tive because no markers have been developed and con-
firmed for reliable immune monitoring during steroid
withdrawal. Progress in this field is discussed elsewhere
in this volume. Also, in kidney transplant recipients a
transcriptional biomarker panel has been suggested to be
associated with reduced costimulatory signaling, immune
quiescence, apoptosis, and memory T cell responses
correlated with an operational state of hyporesponsiveness
[16]. The presence of CD8+CD28+ suppressor T cells was
associated with lower risk of rejection during tapering of
mycophenolate (MMF) and steroids in patients on calci-
neurin inhibitors (CNIs) [16]. Conversely in another study,
cytotoxic T lymphocyte effector molecules (granulysin,
perforin, and granzyme B) were upregulated in adult and
pediatric kidney recipients who had been steroid free during
the first posttransplant year [17]. As these patients had been
entirely stable, the authors interpreted this finding as
paradoxical rather than as a predictor of eventual poor
outcome. It has been suggested that early steroid withdraw-
al (e.g., in the first week) may be more immunologically
beneficial, [3, 18] due to increased apoptosis of reactive
donor specific T cells, [3] and cytokine receptors may not
be upregulated [3, 10]. An effective strategy to the
minimization of immunosuppression will require an accu-
rate method to monitor immunologic risk.
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A discussion of the efficacy of steroids and their proper
place in most transplant treatment protocols is hampered by
[1] individual variability in metabolism, [2] the lack of
clinically available steroid blood levels, [3] little emphasis
on pharmacologic interactions, [4] and the tendency—even
for centers prescribing steroids—to use very low steroid
doses that may be subtherapeutic. For example, many
protocols give 5 mg of prednisone to all chronic patients,
without regard to differences in patient weight or BSA
measurements, which can markedly affect exposure and
efficacy. In some studies including meta-analyses, registry
studies, and clinical trials comparing steroids to non-steroid
regimens are usually discussed without reference to dose or
metabolic parameters. A central tenet of this review is that
the dose of steroids determines both side effects and
efficacy. Similarly, the doses of other drugs that are used
for maintenance immunosuppression in non-steroid proto-
cols will affect the immunologic risks of steroid withdrawal
and should be considered [19, 20].
Prednisone is the most widely used steroid and is
metabolized in the liver, primarily to prednisolone, its
major active metabolite. The shape of the post-dose time-
concentration curve is similar to cyclosporine (CSA) and
tacrolimus (TAC), with peak levels occurring 2–3 h after
ingestion with no measurable levels by 24 h. The timing of
the multiplicity of biologic effects during the dosing cycle
beyond relative lymphopenia and changes in lymphocyte
surface markers at 2–3h[ 21] has not been established.
Steroid effect can be grossly assessed by total lymphocyte
or eosinophil count [13, 21, 22] or by fasting A.M. pre-dose
cortisol levels [23], but no measure of steroid exposure has
been clinically validated or is attempted by virtually any
center. In the usual kidney transplant patient, a Cushingoid
appearance is a poor predictor of increased steroid exposure
[24].
In some studies in stable long-term kidney transplant
recipients, gender and African–American race did not
affect the pharmacokinetics of prednisolone [25]. How-
ever, an early small study suggested a near-significant
50% decrease in methylprednisolone clearance in blacks
[26]. Prednisolone clearance seems to be decreased in
kidney transplant patients relative to normals [27].
Chronic renal failure is associated with an increased free
fraction of prednisolone likely due to hypoalbuminemia
and competitive inhibition of protein binding by uremic
toxins [25]. In obese patients, steroid dosing is complicat-
ed by whether to dose based on ideal or total body weight.
Cortisol production in obesity is increased and has been
found to be a consequence of greater lean body mass.
Adipose tissue has been identified as a specific site for
distribution and clearance of prednisolone [28]. Increased
clearance of prednisolone in obesity may be the result of
secondary effects of obesity including increased cardiac
output, hepatic blood flow, and liver size [28]. However,
the increased clearance may be accompanied by increased
sensitivity to adrenal suppression [28]. Prednisolone dosing
adjustment using total body weight is most appropriate [25].
Liver disease impairs conversion of prednisone to prednis-
olone, yet prednisone-dose-normalized prednisolone expo-
sure is increased in liver transplant patients [27]. Such
metabolic differences in liver and kidney recipients should
be considered as already accounted for by current dosing
protocols.
Whether part of a minimization protocol or not, steroids
are more and more often tapered or discontinued in current
practice [3]. In general clinical practice, selected patients at
relatively lower risk of acute rejection or graft loss are the
preferred populations for steroid withdrawal [3]. Even in
the low dose ranges (e.g., 5 mg daily) that are employed in
current regimens, important dose–response relationships
exist. This should reinforce the almost inescapable propo-
sition that in attempts to taper steroid immunosuppression
to avoid side effects, we also reduce efficacy. The Canadian
study, which showed markedly reduced graft function with
steroid withdrawal was technically an ultra low dose vs.
standard dose trial, as the off prednisone group received on
the average about a milligram of prednisone every other
day [29]. While alternate day steroids may produce less
side effects, early studies demonstrated that they also
provided less immunosuppression than equivalent daily
dosing [30]. In patients who receive steroids, exposure-
effect relationships have largely been validated indirectly.
Prednisolone is hydroxylated by cortisol 6β hydroxylase
and concomitant therapy with anticonvulsants such as
phenytoin results in approximately a 50% increase in
clearance [25]. Additionally, phenobarbital and diphenyl-
hydantoin accelerate metabolism of prednisone and have
been associated with markedly reduced graft survival with
standard steroid regimens (Fig. 1)[ 31]. Indeed, many drugs
Fig. 1 Effect of anticonvulsant therapy on allograft survival
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prednisone [32]. Oral contraceptives significantly increase
steroid exposure [33]. In one study, diltiazem increased
prednisolone exposure approximately 20% in normal
subjects [21]. Consistent with these metabolic effects,
diltiazem has been associated with better long-term graft
survival [34], but the relationship to prednisone exposure is
speculative due to the absence of blood levels. Interactions
between steroid metabolism and CSA or TAC are of lesser
clinical relevance [35].
Notably, no significant interaction between ketoconazole
and prednisolone has been demonstrated [25, 27]. This may
be true for azole antifungals but has not been well studied
with other agents. No significant change in prednisolone
pharmacokinetics was found in patients who were coad-
ministered cyclosporine, sirolimus, macrolide antibiotics, or
nifedipine [36, 37].
Even though current oral daily doses of 5–10 mg/day of
prednisone are low by historical standards, they neverthe-
less appear to have measurable effects. They are roughly
equivalent to replacement doses for complete glucocorti-
coid deficiency, but even in the era of higher steroid dosing,
chronic therapy usually did not induce clinically important
adrenal suppression [38]. Even when “stress doses” of
steroids are truly needed (in higher dose chronically
immunosuppressed populations), arguably only small tran-
sient increases can be justified [39, 40]. A degree of partial
adrenal suppression of uncertain significance has been
suggested in a more recent report [23]. Reinstitution of
low, seemingly “physiologic” doses of steroids can abolish
the rejection-fever-myalgia syndrome in transplanted
patients who have recently returned to dialysis and stopped
immunosuppression. Likewise, withdrawal of such low
“physiologic” doses in ostensibly stable renal transplant
patients in whom graft hyporesponsiveness seems to have
been induced is associated with new antibody formation
(Fig. 2)[ 41]. Withdrawal of chronic, low prednisone doses
of 0.1 mg/kg was dramatically associated with acute or
subacute rejection in 11 of 11 patients transplanted across
ABO barriers [42]. Taken together, these observations
suggest that low-dose steroids do not suppress adrenal
function, but do have significant dose-related therapeutic
effects.
Registry data
Over the last 50 years, most routine, postoperative and
maintenance transplant immunosuppression protocols have
included steroids, although they have been given in lower
and lower doses. Steroid-based regimens were the standard
of care in the azathioprine (AZA) era, throughout most of
the cyclosporine era, and still are for the large majority of
centers in the United States. However, many centers
currently omit steroids ad hoc in selected patients, and
some centers are comfortable doing so in all immunolog-
ically lower risk patients [3]. Steroid avoidance centers cite
studies using the newer agents TAC, MMF, and antibody
induction, which are felt to make steroid immunosuppres-
sion unnecessary for many patients. These latter regimens,
which have the goal of “safe substitution” for steroids,
rather than to induce hyporesponsiveness or tolerance, will
be discussed below.
Despite the widespread use of TAC, MMF, and
induction agents, improvements in long-term kidney
transplant survival have been modest. Most of the
improvement in past decades appears to have been due
to more effective medical and immunologic management
within the first year. For example, the 10-year survival of
deceased donor allografts improved from about 20% in
the seventies to 40% in the nineties, but the half life of
graft loss starting after the first year changed only from
7 . 5y e a r st o8 . 6y e a r s[ 43]. Although these early losses
have been reduced, significant improvements in long-term
survival have not been seen [44]. Consistent with the lack
of an expected improvement in long-term graft survival in
Fig. 2 Antibody formation after
withdrawal of prednisone in
stable kidney transplant
recipients
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detect a benefit of TAC over CSA or MMF over AZA [45].
This question is discussed in more detail in subsequent
sections.
Because registry studies suggest that TAC and MMF
have limited benefit compared to CSA and AZA, many
transplant physicians consider that our major remaining
problems are in chronic, not perioperative, immunosup-
pression. During the perioperative period, the plasticity and
adaptability of the immune system needs to be controlled
day by day. For this reason, many observers feel that steroid
withdrawal has been “studied often, but not studied
well,” i.e., not well studied with relevance to long-term
allograft survival, where a low-risk patient should enjoy
particularly prolonged graft survival, not just be docu-
mented to do well for a year or two. The short-term
studies that begin perioperatively are also less relevant
when they permit induction agents. As survival curves of
induced and noninduced kidney transplants are parallel in
the long term, the early effects of induction may not
provide a sustained ongoing long-term advantage [46].
Induction may delay the emergence of differences in
outcome, but day to day immunosuppression in the chronic
phase of therapy may in fact determine long-term outcome.
Registry studies suggest that tapering immunosuppression in
the long run risks graft loss [4]. It is likely that there is not a
sharp dichotomy between “safe” and “unsafe” regimens, but
that as with most epidemiologic phenomena, a continuum
exits. Thus, an insidious low level immune response can be
misdiagnosed as an “accommodative” state as immunosup-
pression is tapered.
Registry studies are retrospective and attempt with
varying degrees of success to control for unintended
variables that may confound a hypothesis. Some registry
studies show no detriment of steroid avoidance to graft
survival [47]. However, many patients that were initially
steroid free will return to steroid therapy [47, 48]. If
analyzed by intent to treat, a large number of patients
returning to steroid treatment may obscure the results of
registry studies. Registry studies are also complicated by
the fact that “safer” patients often remain on steroids, and it
is difficult to adjust the analysis to account for this bias.
This is strikingly illustrated by retrospective analyses
attempting to identify matched controls who remained on
steroids; that analysis suggested that steroids were actually
deleterious to graft function [49, 50], an “observation” that
prompted the Canadian trial (see below) [29].
Steroid avoidance studies
Many “successful” steroid avoidance protocols were
reported well before the advent of Neoral, TAC, or MMF.
Protocols have always either prescribed no steroids post-
operatively, stopped steroids in the first weeks after
transplantation, or tapered and discontinued them after
several months. Study end points are usually rejection
episodes, for-cause biopsies and/or changes in renal
function. Historically, many studies have found more
histological evidence of rejection with steroid withdrawal,
especially in the higher immunologic risk groups but with
little effect on graft function [51]. This has been interpreted
by critics to indicate that graft survival will eventually be
reduced by steroid avoidance for most patients and has
prompted cautious recommendations that steroid avoidance
be treated as unproven or even experimental [3, 52]. Meta-
analyses of course are only as good as the studies they
summarize. A recent meta-analysis of nine steroid with-
drawal studies [53], attempted to neutralize the effect of
induction therapy to obscure short-term differences by
reviewing only studies that did not include induction in
their protocols [53]. It concluded that steroid withdrawal
was acceptable with TAC immunosuppression but not with
CSA [53]. However, while indeed not part of any study
protocol, induction was liberally and/or selectively used in
several studies, and only two of the nine studies were TAC
based [54]. The meta-analysis also included a large CSA
study that used higher steroid doses and higher risk patients
that had to be terminated for increased rejection in the off-
steroid arm [54]. A comparable TAC study was not
included with the two TAC studies that were analyzed.
Thus, this well-received meta-analysis [55] included a
diverse set of study protocols that may confound any
interpretation of the analysis. Another careful meta-analysis
concluded that steroid withdrawal was associated with an
increased rate of rejection as well as increased side effects,
but most studies included in the analysis were of poor
quality [56].
Whether we are committing a “subgroup fallacy” by
treating lower risk patients as different from the higher risk
patients, especially in light of the persisting problems that
have occurred with improving long-term allograft survival,
is discussed elsewhere in this chapter.
Relevant United Network for Organ Sharing (UNOS)
and/or single center Organ Procurement and Transplanta-
tion Network (OPTN) data are useful in evaluating
published experience from the USAwith cohorts of patients
in whom steroids have been withdrawn. These public
outcome data should be compared to graft survival data
reported steroid withdrawal studies to assess overall risk of
the study cohorts. In uncontrolled single center studies, in
which, e.g., all patients at the center are supposed to be
steroid free, the center’s UNOS or OPTN data can be
compared with the data that appear in the study report. In
some studies, these data do not seem concordant [57–59].
The exceedingly well-done multicenter Astellas steroid
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survival in both cohorts that far exceeded UNOS national
3-year averages [60], suggesting that, by chance, partici-
pating centers preferentially entered low-risk patients.
The Canadian study from over two decades ago [29] and
the recent Astellas-sponsored trial [60] are the two best
steroid avoidance studies in several respects—placebo
controlled, prospective, randomized, and reasonably long
term. The seminal study of the efficacy of chronic steroid
therapy and the risks of withdrawal was the randomized,
placebo controlled, Canadian study published in 1992 [29].
Eleven Canadian centers enrolled patients from 1982 to
1985. Enrollment commenced at 90 days posttransplant, but
only in stable patients with serum creatinine of ≤2.2 mg/dl.
Participantswererandomized1:1,andallreceivedtheoriginal
widely used formulation of cyclosporine (Sandimmune).
Trough levels averaged 100–110 ng/ml. Importantly, predni-
sone was dosed by weight, tapered to 0.2 mg/kg every other
day by 6 months and discontinued per protocol. No induction
or third drug (e.g., azathioprine) was given as part of the
protocol.Additionalsteroidswereoptionalatthe discretionof
the center’s physicians, but the placebo vs. prednisone
outcomes were analyzed based on intention to treat.
Forty-three percent of all center patients were enrolled
(with serum creatinine ≤2.2 mg/dl and no active rejection).
Increased immunologic risk was not an exclusion criterion,
in part because some previous uncontrolled experience had
suggested that steroids given with CSA increased the risk
of rejection [29]. By 1.3 years, 120 of 260 patients had
been withdrawn from the placebo group and treated with
prednisone, but per study design, remained in the placebo
group for 2 years for analysis. Thirty-three subjects (13% of
the total) in the placebo group received prednisone by
mistake, and they were also analyzed in the placebo group.
Graft survival at 5 years was 73% in the placebo group and
85% in the steroid group. Interestingly, differences were
even more striking in higher risk patients such as retrans-
plants. In the manuscript, renal function was only compared
between subjects in the on-steroid and off-steroid groups
with functioning grafts. Thus, the exclusion of nonfunc-
tioning grafts would markedly diminish the apparent overall
effect of steroid withdrawal on graft function. As reported,
serum creatinine and calculated Cockcroft–Gault creatinine
clearances differed at 6 months into the protocol, and the
difference stayed relatively constant with creatinine clear-
ances lower in the placebo group by approximately 10%.
Data were presented graphically and do not allow precise
analysis. However, if a creatinine value of 8 mg/dl is
assigned to patients in either arm who returned to dialysis
and these patients then included in a cumulative analysis,
the long-term difference in serum creatinine between the
two cohorts approaches 0.3–0.4 mg/dl with the lower
creatinine in the steroid therapy group.
In summary, the Canadian steroid withdrawal study
showed a benefit from steroid therapy. It showed significant
differences in long-term graft survival and also in renal
function in patients who had not yet lost their grafts, that is,
it showed an ongoing effect of steroid avoidance. The
Canadian study did not use TAC or MMF. Azathioprine use
was not part of the protocol nor was AZA use, if any,
reported in the analysis. Thus, a potential criticism of the
study is that newer agents, e.g., tacrolimus and mycophe-
nolate mofetil, would be more potent and diminish the
importance of these striking results. In fact, some editorials
have suggested that TAC (to replace CSA) and MMF (to
supplement TAC and/or replace AZA) may have made the
Canadian study irrelevant to current practices [18, 60, 61].
This possibility was addressed by the more recent
Astellas steroid withdrawal study [60]. Published in 2008,
the Astellas study was only the second long-term random-
ized, placebo controlled trial of steroid withdrawal in
kidney transplant recipients. Three hundred ninety-seven
patients transplanted between 1999 and 2002 were enrolled.
The study involved lower risk patients with initially
functioning grafts, who either had prednisone stopped by
7 days post transplant or tapered to 5 mg per day by
6 months as maintenance therapy. Both groups received
postoperative antibody induction, TAC, and MMF. At
5 years, there was no significant difference in patients
reaching the composite end point of death, acute rejection,
or graft loss. Side effects were remarkably similar in both
groups, with significant but small steroid-associated
increases in triglyceride values and in weight gain,
averaging about a pound a year. For-cause biopsies showed
chronic allograft nephropathy in 9.9% of the steroid
withdrawal group vs. 4.1% in the steroid treated group. At
5 years, serum creatinine in both groups remained at about
1.5 mg/dl. Five-year graft survival was not reported
separately but was over 90% in both groups. In comparison
from 1997 to 2004, the average OPTN 3-year survival for
living donor kidneys was about 88%, for deceased donor
kidneys about 78%, and for all primary kidney transplants
about 82% (www.ustransplant.org). Thus, the 5-year out-
comes of both the steroid treated and off-steroid groups in
the Astellas study were superior to the overall 3-year results
reported in the USA to OPTN, suggesting disproportionate,
unintended inclusion of low-risk patients in both arms of
the Astellas study.
While the sophisticated and careful trial design and
analysis of the results were singularly helpful in assessing
efficacy and side effects attributable to chronic steroid
immunosuppression, interpretation of the Astellas trial is
complicated by the fact that low-risk patients were entered
and steroid doses were low (i.e., “almost no steroid”). The
few documented steroid-related side effects suggest that
drug exposure was indeed low. Thus, the Astellas study
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therapy, as the risks were minimal. Others report have
questioned whether the minimal side effects associated with
low-dose steroids are sufficient to justify withdrawal of
prednisone [3, 62, 63].
In epidemiological studies, one needs a population at
reasonable risk, some of whom have undergone a strong
intervention, and differ only with respect to that interven-
tion. To the extent that risk and/or the strength of the
intervention are low, a longer observation period is needed
to evaluate a hypothesis of equivalency of outcome. This
low-risk/minimal intervention factor may complicate the
generalizability of the Astellas study to the clinical use of
steroids in long-term maintenance immunosuppression.
Steroid side effects
Steroids have many undesirable side effects, and many
small, suboptimally controlled studies report less risk of
exacerbating diabetes, hypertension, and hypercholesterol-
emia with steroid avoidance. However, many do not report
the steroid doses used, but as previously discussed, dose is
central to efficacy and the incidence of side effects. Also, it
is important to consider that side effects from steroids have
been of lesser magnitude in the current era of overall lower
doses [3, 62, 63]. Steroid overexposure (or underexposure)
might be plausibly deduced in the few patients who are
taking other drugs that affect the metabolism of steroids
[32]. But until we have assays for steroid exposure, we
cannot accurately assess it. Therefore, a steroid side effect
does not give one a clear rationale to reduce the dose
“safely.” For most patients who are receiving target-range
exposures of critical drugs, control of a side effect while
keeping the dose unchanged would seem more prudent. In
fact, studies that show the most beneficial immunologic
effect of steroids also use higher doses, but still in the “low”
dose range [64]. The Canadian trial [29] used weight based
(i.e., higher) doses and higher risk groups, but the side
effect profiles were not well described. As discussed in
previous sections, the well-controlled Astellas trial [60]
used lower doses with lower risk groups, showing a small
immunologic disadvantage to steroid avoidance. The side
effect profiles were so similar on and off steroids that the
trial as easily argues against pursuing steroid avoidance as
it argues for it. The Astellas trial used a relatively small,
fixed daily dose of 5 mg of prednisone in all patients,
regardless of size, and found no difference in the incidence
of diabetes or hypertension, an exceedingly small differ-
ences in triglycerides and a differential weight gain of only
5.1 vs. 7.7 kg at 5 years (or about a pound a year). In higher
dose eras, others have reported similar findings [65].
Steroids increase the HDL content in serum lipids which
may complicate the assessment of cardiovascular risks [66].
Protocols have been developed to control weight gain [67]
and bone disease [68], for example that does not involve
steroid dose reduction. A possible positive side effect of
steroids might be a reduction in CNI nephrotoxicity [69].
Omitting steroids may result in reduced expression of P
glycoprotein [35]. Inhibition of that system at the surface of
renal tubular cells may lead to increased intracellular
accumulation and increased fibrosis [70]. For use during
pregnancy, glucocorticoids, TAC, and CSA are rated class
C teratogens, with MMF, sirolimus, and AZA rated at
higher risk at class D [71].
Have tacrolimus and mycophenolate made steroids
unnecessary?
On the basis of data generated prior to the Astellas study,
whether TAC and MMF would be likely to “make
Canadian study irrelevant” is open to question. Three early,
prospective, well designed, and pivotal studies [72–74]
defined MMF as a new and more potent agent for acute and
chronic immunosuppression [61]. Using CSA and predni-
sone as baseline immunosuppression, MMF was directly
compared to AZA in two studies and to placebo in a third.
Subjects were entered at the time of transplant and primary
nonfunction was important in determining differences in
graft survival [75]. In all three studies, the MMF group
experienced less early mild rejection [76] and graft loss.
However, in none of the three studies was there a finding of
an ongoing effect of MMF beyond 6 months—only a
maintained early difference that was generated by the early
graft losses in all three trials. The Canadian study did not
use AZA; therefore, the experience in the early and
influential MMF vs. placebo study would be particularly
relevant in assessing the contribution of MMF when added
to a CSA and steroid regimen. This study compared CSA,
MMF, and steroids to CSA, steroids, and a placebo, but
serum creatinine values in the two groups were identical at
1 year, [77] and, inexplicably, no creatinine or other renal
function data were included in the 3-year report [72]. There
was no difference in graft loss between the study groups
beyond 1 year as the survival curves remained parallel. The
two other studies comparing MMF to AZA showed a
similar lack of ongoing long-term effect, either in graft loss
or in a separation in the serum creatinine values in the two
cohorts of patients with functioning grafts [73, 74].
Defenders of MMF as a major advance in immunosuppres-
sion argue that these three early pivotal studies were not
powered to show long-term effects on graft survival or graft
function [61], but each study was about as large as the
Canadian study, which did show striking differences in
both. If we apply the same standards, it is hard to accept the
Semin Immunopathol (2011) 33:157–167 163MMF data as even partially convincing without giving even
more credence to the Canadian data that suggest an ongoing
beneficial effect for steroid immunosuppression. In sum-
mary, we might accept MMF as an improvement in current
immunosuppression, but not by the evidence, a sufficient
improvement to justify dismissing the Canadian study and
making the cessation of low-dose steroid therapy safer.
Tacrolimus has also been held to be a sufficient
improvement over CSA to justify steroid-free therapy in
many patients in spite of the findings of the Canadian study
[29]. However, many early pivotal, prospective studies
comparing CSA and TAC can be found that show minimal
to no differences in serum creatinine over the first few
years, and even less effect on graft survival [78, 79].
Registry studies suggest equivalence of CSA and TAC [80].
A superiority of TAC over CSA has not been seen by the
University of Minnesota [81], that consistently reports
excellent survival results with steroid-free protocols that
are not worse than on—steroid historical controls, i.e., by
these accounts TAC provides steroid-free outcomes equiv-
alent to CSA. Considering the totality of TAC–CSA
studies, the evidence for some degree of superiority of
TAC over CSA appears better than the evidence for relative
superiority of MMF. But even the best evidence supporting
TAC as an improvement over CSA in chronic immunosup-
pression showed a smaller benefit than that offered by
steroids over no steroids in the Canadian study. MMF was a
costly drug, and the incidence of diabetes was markedly
increased when TAC was used in place of CSA (package
inserts). As discussed in the next section, despite their
drawbacks, no one has attempted typical “steroid-type”
studies that probably would have readily identified low-risk
subgroups, in which these newer drugs could have been
avoided.
Is a “safe” steroid-free subgroup a defensible concept?
In any study, whether it is a registry analysis or any other
clinical comparison, some patients in various subgroups
will usually do well regardless of the intervention.
Certainly, under the conditions of the study (short term,
induction, etc.) there can be little doubt of acceptable
outcomes when steroids are not part of transplant immuno-
suppression. But as a whole, the transplant profession has
applied different standards to steroid use than it has to its
newer, proprietary agents. When TAC and MMF were first
introduced in spite of respective drawbacks of increased
diabetic risk or cost, we did not try to identify “safe”
subgoups, in which the newer agent was “unnecessary.”
Given the strength of the evidence, this probably would not
have been hard to do. But we instead recommended the
newer drugs for all patients when they showed benefit in
mixed-risk cohorts. Presumably, this was to maximize
protection against long term, insidious rejection in groups
that were at low short-term risk. Efficacy in higher risk
groups in the short run was thought to imply benefit for
lower risk groups in the longer run. Even by its defenders,
steroid withdrawal in patients at higher immunologic risk
has long been recognized as riskier and less advisable [28,
29, 82, 83]. But we attempt steroid withdrawal on lower
risk patients as if they were somehow fundamentally
different from higher risk patients, who instead might be
so called “canaries in the mine,” that warned us of what
was to come for the rest. We may have overestimated the
protection afforded by MMF and TAC over the past two
decades. As use of these agents has increased and the
practice of steroid withdrawal has increased [3], we have
not seen the improvement in long-term graft survival that
many expected [44]. Yet, we continue to pursue steroid
withdrawal for “safer” groups, as if lessons learned in one
subpopulation of transplant recipients should not be carried
over to the whole.
Summary
Many clinicians accept that steroids were an essential part
of maximally effective chronic immunosuppression in past
decades but some suggest that they are no longer necessary,
at least in low-risk populations when our newer more
potent drugs are used. This chapter summarizes the data
that may support or undermine this view. (1) Chronic
immunosuppression trials need to be chronic. Potential
differences in long-term outcome will be minimized by
short-term antibody induction studies in low-risk patients,
particularly if the on-steroid arm receives very low doses.
(2) In the early trials as well as in many subsequent studies,
the widely accepted evidence for the superiority of MMF
and TAC was not as strong as the evidence for the benefit
of steroids in the Canadian study. The comparable Astellas
trial found small differences favoring steroids in outcome
and minimal side effects at 5 years, which may be
attributable to the inclusion of low-risk patients and low
doses of steroid. (3) Despite good reason to try, because of
belief in overall long-term efficacy for all our patients, we
have not attempted to find subgroups for which our newer
agents, TAC and MMF, were not needed. (4) The lack of
improvement in graft survival in the era of MMF and TAC
suggests suboptimal additional protection afforded by
current strategies. As the practice of steroid withdrawal
has increased, we have not seen the improvement in long-
term graft survival that many expected with our newer
agents. (5) The basic principles of exposure, efficacy, and
outcome epidemiology apply to all our immunosuppressive
agents and this includes steroids. The transplant effort will
164 Semin Immunopathol (2011) 33:157–167benefit if steroids are dosed and steroid studies evaluated
using the same standards that have been applied to our
proprietary drugs.
A heterogeneous transplant population will always
provide heterogeneity of responses to all of our drug
regimens. Clearly some patients continue to do well when
followed for several years when steroid free, and some have
clearly benefitted long term from steroid avoidance. It is up
to the individual clinician and center to discuss and decide
with properly informed patients on the correct approach to
steroid avoidance, with the realization that steroids seem to
“add something” to transplant populations as a whole, and
we have no accepted way to reverse a fully established
chronic rejection. If steroids are to be avoided in low-risk
patients, the decision must weigh the benefits of, e.g.,
perhaps 25 years of graft function on low-dose steroids
against the real risk of perhaps only 20 years of function off
steroids. The side effects of low-dose chronic steroid
regimens must be weighed against the risks of accelerated
occurrence off steroids of the “side effects” of reduced renal
function as the transplant fails and an eventual return to
chronic dialysis [84, 85].
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